New lung cancer treatment combinations for KRAS G12C mutation

Plain-English translation of NCT06793215 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a new combination of (a targeted therapy) and (an immunotherapy) works better than the standard treatment of combined with chemotherapy for people with advanced lung cancer that has a KRAS G12C mutation. The study will compare how well these two different treatment approaches work and how safe they are.

Currently, people with this specific type of lung cancer are typically treated with chemotherapy combined with immunotherapy. Researchers want to see if using the medication with a different immunotherapy approach might work better or cause fewer side effects.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic non-squamous non-small cell lung cancer with a KRAS G12C mutation
your lung cancer has not been treated with any systemic therapy before
your cancer cannot be cured with surgery or radiation therapy alone
your doctor confirms you can tolerate chemotherapy
you have measurable disease that can be tracked on scans
you are in good enough general health (ECOG performance status 0 or 1)

You likely don't qualify if…

you have untreated or actively worsening brain metastases (cancer spread to the brain)
you have been treated with KRAS inhibitors or similar targeted therapies before
you have a history of other cancers in the past 5 years (with limited exceptions)
you have significant bowel or digestive problems that would prevent you from absorbing an oral medication
you have received recent chemotherapy, radiation, or immunotherapy within the specified timeframes

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new medication combination (a daily pill plus infusions every 3 weeks) or the standard treatment (infusions every 3 weeks). You will attend regular clinic visits for blood tests, scans to measure your cancer, and to receive your treatment. The trial involves 600 participants total, and you would continue treatment as long as it's working and you're tolerating it well.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

New lung cancer treatment combinations for KRAS G12C mutation

What is this trial?

Do you qualify?

What participation looks like

Trial locations(280 sites)